HomePharmacologyAntithrombotic Anticoagulants

Antithrombotic Anticoagulants

View Category

Antithrombotic Anticoagulants

Low-Dose Rivaroxaban After Peripheral Angioplasty: Effectiveness and Safety in Real-World Clinical Practice

Following lower limb revascularization, optimal medical therapy includes antiplatelet agents, high-intensity statins, and control of cardiovascular risk...
Dr. Juan Manuel Pérez -
Learn More
Acute coronary syndromes

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing...
Dr. Andrés Rodríguez -
Learn More
Antiplatelet

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially...
Dr. Omar Tupayachi -
Learn More
Antithrombotic Anticoagulants

TCT 2025 | STORM-PE: Mechanical Thrombectomy with Penumbra Lightning+AC vs. Anticoagulation Alone in Intermediate-High Risk PE

Intermediate-high risk pulmonary embolism (PE) remains a therapeutic challenge. Anticoagulation is still the standard treatment, albeit with...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

HELP-PCI: A Fleeting Advantage of Early Heparin in ST-Elevation Myocardial Infarction?

In ST-elevation myocardial infarction (STEMI), immediate reperfusion through primary percutaneous coronary intervention (pPCI) remains the treatment of...
Dr. Omar Tupayachi -
Learn More
Antithrombotic Anticoagulants

ESC 2025 | HI-PRO: Extended Apixaban for Recurrence Prevention in Provoked DVT/PE

Patients with provoked venous thromboembolism (VTE) usually discontinue anticoagulation after 3 to 6 months. However, in the...
Dr. Omar Tupayachi -
Learn More
Antithrombotic Anticoagulants

8 Questions About Left Atrial Appendage Closure: Contributions from the 2025 SCAI/HRS Review

Courtesy of Dr. Juan Manuel Pérez. Percutaneous left atrial appendage occlusion (LAAO) is an alternative to oral anticoagulation...
Dr. Juan Manuel Pérez -
Learn More
Antithrombotic Anticoagulants

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will...
Dr. Omar Tupayachi -
Learn More